HUP0400466A3 - G-csf conjugates - Google Patents

G-csf conjugates

Info

Publication number
HUP0400466A3
HUP0400466A3 HU0400466A HUP0400466A HUP0400466A3 HU P0400466 A3 HUP0400466 A3 HU P0400466A3 HU 0400466 A HU0400466 A HU 0400466A HU P0400466 A HUP0400466 A HU P0400466A HU P0400466 A3 HUP0400466 A3 HU P0400466A3
Authority
HU
Hungary
Prior art keywords
csf conjugates
csf
conjugates
Prior art date
Application number
HU0400466A
Other languages
English (en)
Original Assignee
Maxygen Holdings Ltd Georgetow
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27222576&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUP0400466(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US09/904,196 external-priority patent/US6555660B2/en
Application filed by Maxygen Holdings Ltd Georgetow filed Critical Maxygen Holdings Ltd Georgetow
Publication of HUP0400466A2 publication Critical patent/HUP0400466A2/hu
Publication of HUP0400466A3 publication Critical patent/HUP0400466A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
HU0400466A 2001-07-11 2002-07-10 G-csf conjugates HUP0400466A3 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US09/904,196 US6555660B2 (en) 2000-01-10 2001-07-11 G-CSF conjugates
DKPA200200447 2002-03-22
DKPA200200708 2002-05-08
PCT/DK2002/000482 WO2003006501A2 (en) 2001-07-11 2002-07-10 G-csf conjugates

Publications (2)

Publication Number Publication Date
HUP0400466A2 HUP0400466A2 (hu) 2005-01-28
HUP0400466A3 true HUP0400466A3 (en) 2006-01-30

Family

ID=27222576

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0400466A HUP0400466A3 (en) 2001-07-11 2002-07-10 G-csf conjugates

Country Status (16)

Country Link
US (4) US7550565B2 (hu)
EP (1) EP1425304B9 (hu)
JP (1) JP4444652B2 (hu)
KR (1) KR100961859B1 (hu)
AT (1) ATE468862T1 (hu)
AU (1) AU2002325819B2 (hu)
BR (1) BR0211071A (hu)
CA (1) CA2452582C (hu)
DE (1) DE60236522D1 (hu)
HU (1) HUP0400466A3 (hu)
IL (1) IL159524A0 (hu)
MX (1) MXPA04000231A (hu)
NO (1) NO20040093L (hu)
NZ (1) NZ530545A (hu)
PL (1) PL371781A1 (hu)
WO (1) WO2003006501A2 (hu)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7214660B2 (en) 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7173003B2 (en) 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
EP2338333B1 (en) 2003-04-09 2017-09-06 ratiopharm GmbH Glycopegylation methods and proteins/peptides produced by the methods
US9005625B2 (en) 2003-07-25 2015-04-14 Novo Nordisk A/S Antibody toxin conjugates
EP1673387B1 (en) * 2003-10-10 2010-09-15 Novo Nordisk A/S Il-21 derivatives
US20060228331A1 (en) 2003-10-10 2006-10-12 Novo Nordisk A/S IL-21 Derivatives and variants
US7220407B2 (en) 2003-10-27 2007-05-22 Amgen Inc. G-CSF therapy as an adjunct to reperfusion therapy in the treatment of acute myocardial infarction
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
BRPI0417342A (pt) * 2003-12-03 2007-04-17 Neose Technologies Inc fator estimulante de colÈnia de granulócitos glicopeguilado
EP1586334A1 (en) * 2004-04-15 2005-10-19 TRASTEC scpa G-CSF conjugates with peg
SI2586456T1 (sl) 2004-10-29 2016-05-31 Ratiopharm Gmbh Preoblikovanje in glikopegliacija fibroblastnega rastnega faktorja (FGF)
ATE544463T1 (de) 2004-11-05 2012-02-15 Univ Northwestern Verwendung von scf und g-scf bei der behandlung von hirnischämie und neurologischen störungen
JP2006137678A (ja) * 2004-11-10 2006-06-01 Shionogi & Co Ltd インターロイキン−２組成物
AU2006203792B2 (en) 2005-01-10 2011-11-03 Ratiopharm Gmbh Glycopegylated Granulocyte Colony Stimulating Factor
WO2006121569A2 (en) 2005-04-08 2006-11-16 Neose Technologies, Inc. Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
US7381805B2 (en) * 2005-06-01 2008-06-03 Maxygen Holdings, Ltd. Compositions comprising mixtures of positional PEG isomers of PEGylated G-CSF
KR100694994B1 (ko) 2005-06-13 2007-03-14 씨제이 주식회사 사람 과립구 콜로니 형성인자 동종체
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
KR20080072639A (ko) * 2005-10-27 2008-08-06 주식회사 펩트론 생리활성 기질-혈액 단백질 복합체 및 이를 이용하는생리활성 기질의 안정화 방법
WO2007056191A2 (en) 2005-11-03 2007-05-18 Neose Technologies, Inc. Nucleotide sugar purification using membranes
JP2009544327A (ja) 2006-07-21 2009-12-17 ノヴォ ノルディスク アー／エス Ｏ−結合型グリコシル化配列によるペプチドのグリコシル化
US9176145B2 (en) 2006-07-21 2015-11-03 Femalon S.P.R.L. Kit for predicting implantation success in assisted fertilization
MY150687A (en) 2006-07-21 2014-02-28 Femalon S P R L Assay and kit for predicting implantation success in assisted fertilisation
CN101573133B (zh) * 2006-07-31 2014-08-27 诺沃-诺迪斯克有限公司 Peg化延长的胰岛素
ITMI20061624A1 (it) * 2006-08-11 2008-02-12 Bioker Srl Mono-coniugati sito-specifici di g-csf
US20100075375A1 (en) 2006-10-03 2010-03-25 Novo Nordisk A/S Methods for the purification of polypeptide conjugates
EP2144923B1 (en) 2007-04-03 2013-02-13 BioGeneriX AG Methods of treatment using glycopegylated g-csf
US9493499B2 (en) 2007-06-12 2016-11-15 Novo Nordisk A/S Process for the production of purified cytidinemonophosphate-sialic acid-polyalkylene oxide (CMP-SA-PEG) as modified nucleotide sugars via anion exchange chromatography
WO2009108806A1 (en) 2008-02-27 2009-09-03 Novo Nordisk A/S Conjugated factor viii molecules
JOP20190083A1 (ar) 2008-06-04 2017-06-16 Amgen Inc بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها
JP2012503014A (ja) * 2008-09-19 2012-02-02 マキシジェン， インコーポレイテッド マルチ−ｐｅｇ化顆粒球コロニー刺激因子（ｇ−ｃｓｆ）変異体の投与による放射線誘発好中球減少症の処置のための方法
SG195542A1 (en) 2008-10-10 2013-12-30 Amgen Inc Fgf21 mutants and uses thereof
DK3248610T3 (da) 2009-05-05 2024-01-15 Amgen Inc Fgf21-mutanter og anvendelser deraf
WO2010129600A2 (en) 2009-05-05 2010-11-11 Amgen Inc. Fgf21 mutants and uses thereof
AU2010262927A1 (en) * 2009-06-17 2012-01-19 Amgen Inc. Chimeric FGF19 polypeptides and uses thereof
CA2781099A1 (en) 2009-11-17 2011-05-26 Janssen Biotech, Inc. Improved bacterial membrane protein secrection
AU2010326024A1 (en) 2009-12-02 2012-07-05 Amgen Inc. Binding proteins that bind to human FGFR1c, human beta-Klotho and both human FGFR1c and human beta-Klotho
UA109888C2 (uk) * 2009-12-07 2015-10-26 ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ
ES2639398T3 (es) 2010-03-04 2017-10-26 Pfenex Inc. Método para producir proteína de interferón recombinante soluble sin desnaturalización
CA2794740C (en) 2010-04-01 2019-12-31 Pfenex Inc. Methods for g-csf production in a pseudomonas host cell
EP2558497A2 (en) 2010-04-15 2013-02-20 Amgen Inc. Human fgf receptor and beta-klotho binding proteins
US9320777B2 (en) 2011-05-13 2016-04-26 Bolder Biotechnology, Inc. Methods and use of growth hormone supergene family protein analogs for treatment of radiation exposure
WO2016013725A1 (ko) * 2014-07-23 2016-01-28 주식회사 이큐스앤자루 과립구 콜로니 자극인자 변이 단백질 또는 이의 트랜스페린 융합 단백질을 유효성분으로 포함하는 약학적 조성물
KR101623906B1 (ko) * 2014-07-23 2016-05-24 주식회사 이큐스앤자루 과립구 콜로니 자극인자 변이 단백질 또는 이의 트랜스페린 융합 단백질을 유효성분으로 포함하는 약학적 조성물
AU2015301936B2 (en) 2014-08-11 2019-03-07 Delinia, Inc. Modified IL-2 variants that selectively activate regulatory T cells for the treatment of autoimmune diseases
KR101950916B1 (ko) * 2014-09-10 2019-02-21 크링글파마 가부시키가이샤 신경 질환의 치료에 적절한 hgf 제제
CN107949565A (zh) * 2015-06-11 2018-04-20 安姆生物制药有限责任公司 聚乙二醇化粒细胞集落刺激因子(gcsf)
US11229683B2 (en) 2015-09-18 2022-01-25 Bolder Biotechnology, Inc. Hematopoietic growth factor proteins and analogs thereof and angiotensin converting enzyme inhibitors for treatment of radiation exposure
US20170204154A1 (en) 2016-01-20 2017-07-20 Delinia, Inc. Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
WO2018089420A1 (en) 2016-11-08 2018-05-17 Delinia, Inc. Il-2 variants for the treatment of autoimmune diseases

Family Cites Families (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3209596C2 (de) * 1982-03-17 1985-10-03 Uni-Cardan Ag, 5200 Siegburg Gleichlaufdrehgelenk
WO1985000817A1 (en) 1983-08-10 1985-02-28 Amgen Microbial expression of interleukin ii
JPS61227526A (ja) 1984-07-25 1986-10-09 Chugai Pharmaceut Co Ltd 新規なコロニー刺激因子
DE3680613D1 (de) 1985-02-08 1991-09-05 Chugai Pharmaceutical Co Ltd Menschlicher granuloxcyt-kolonie-stimulierungsfaktor.
US4810643A (en) 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
JPS63500636A (ja) 1985-08-23 1988-03-10 麒麟麦酒株式会社 多分化能性顆粒球コロニー刺激因子をコードするｄｎａ
US6004548A (en) * 1985-08-23 1999-12-21 Amgen, Inc. Analogs of pluripotent granulocyte colony-stimulating factor
JPS6263335A (ja) 1985-09-13 1987-03-20 Fuji Photo Film Co Ltd 化学反応情報の処理方法
DE3681551D1 (de) 1985-09-30 1991-10-24 Chugai Pharmaceutical Co Ltd Menschlicher granulozyten-colony stimulierender faktor.
EP0230980B2 (en) 1986-01-22 1996-03-20 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical agent for promoting the recovery of hemopoietic capacity
US4908773A (en) 1987-04-06 1990-03-13 Genex Corporation Computer designed stabilized proteins and method for producing same
DK203187A (da) 1986-04-22 1987-10-23 Immunex Corp Human g-csf proteinekspression
AU7675487A (en) 1986-08-11 1988-05-19 Cetus Corporation Expression of granulocyte colony-stimulating factor
US4704692A (en) 1986-09-02 1987-11-03 Ladner Robert C Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US5214132A (en) * 1986-12-23 1993-05-25 Kyowa Hakko Kogyo Co., Ltd. Polypeptide derivatives of human granulocyte colony stimulating factor
US5681720A (en) 1986-12-23 1997-10-28 Kyowa Hakko Co., Ltd. DNA encoding human granulocyte colony stimulating factor plasmids and host cells comprising same, and methods of expressing the encoded polypeptide
DK174044B1 (da) 1986-12-23 2002-05-06 Kyowa Hakko Kogyo Kk Polypeptid afledt fra human granulocytkolonistimulerende faktor, og fremgangsmåde til fremstilling deraf, DNA kodende for nævnte polypeptid, rekombinant plasmid indeholdende nævnte DNA, og mikroorganismer indeholdende nævnte rekombinante plasmid.......
US5362853A (en) 1986-12-23 1994-11-08 Kyowa Hakko Kogyo Co., Ltd. Polypeptide derivatives of human granulocyte colony stimulating factor
US4853871A (en) 1987-04-06 1989-08-01 Genex Corporation Computer-based method for designing stablized proteins
GB2213821B (en) 1987-12-23 1992-01-02 British Bio Technology Synthetic human granulocyte colony stimulating factor gene
US4904584A (en) * 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
CA1340810C (en) 1988-03-31 1999-11-02 Motoo Yamasaki Polypeptide derivatives of human granulocyte colony stimulating factor
EP0344796B1 (en) 1988-06-03 1994-09-21 Chugai Seiyaku Kabushiki Kaisha Crystalline human granulocyte colony stimulating factor and process for preparing the same
US5025388A (en) * 1988-08-26 1991-06-18 Cramer Richard D Iii Comparative molecular field analysis (CoMFA)
US5218092A (en) 1988-09-29 1993-06-08 Kyowa Hakko Kogyo Co., Ltd. Modified granulocyte-colony stimulating factor polypeptide with added carbohydrate chains
US5349052A (en) * 1988-10-20 1994-09-20 Royal Free Hospital School Of Medicine Process for fractionating polyethylene glycol (PEG)-protein adducts and an adduct for PEG and granulocyte-macrophage colony stimulating factor
US5104651A (en) 1988-12-16 1992-04-14 Amgen Inc. Stabilized hydrophobic protein formulations of g-csf
US20020177688A1 (en) 1988-12-22 2002-11-28 Kirin-Amgen, Inc., Chemically-modified G-CSF
US6166183A (en) * 1992-11-30 2000-12-26 Kirin-Amgen, Inc. Chemically-modified G-CSF
EP0401384B1 (en) 1988-12-22 1996-03-13 Kirin-Amgen, Inc. Chemically modified granulocyte colony stimulating factor
US5122614A (en) 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5109119A (en) 1989-06-06 1992-04-28 Schering Corporation Crystalline r-h-gm-csf and method
IE66494B1 (en) 1989-09-26 1996-01-10 Immunex Corp Granulocyte-colony stimulating factor receptors
US5265030A (en) 1990-04-24 1993-11-23 Scripps Clinic And Research Foundation System and method for determining three-dimensional structures of proteins
GB9107846D0 (en) 1990-04-30 1991-05-29 Ici Plc Polypeptides
US5399345A (en) 1990-05-08 1995-03-21 Boehringer Mannheim, Gmbh Muteins of the granulocyte colony stimulating factor
DE4014750A1 (de) 1990-05-08 1991-11-14 Boehringer Mannheim Gmbh Muteine des granulozyten-stimulierenden faktors (g-csf)
JP3249147B2 (ja) 1990-06-01 2002-01-21 キリン−アムジエン・インコーポレーテツド 生理活性蛋白含有経口製剤
IE912365A1 (en) 1990-07-23 1992-01-29 Zeneca Ltd Continuous release pharmaceutical compositions
WO1992004455A1 (en) 1990-08-29 1992-03-19 Genetics Institute, Inc. Multidomain hematopoiesis stimulators
US5124297A (en) 1990-12-07 1992-06-23 Amoco Corporation Olefin polymerization and copolymerization catalyst
DE4105480A1 (de) 1991-02-21 1992-08-27 Boehringer Mannheim Gmbh Verbesserte aktivierung von rekombinanten proteinen
GB2253852B (en) 1991-02-26 1995-03-22 Ici Plc Vector for expression of heterologous polypeptide comprising inducible selection system
US5157736A (en) 1991-04-19 1992-10-20 International Business Machines Corporation Apparatus and method for optical recognition of chemical graphics
ATE196548T1 (de) 1991-05-10 2000-10-15 Genentech Inc Auswählen von agonisten und antagonisten von liganden
AU2408292A (en) * 1991-07-11 1993-02-11 Regents Of The University Of California, The A method to identify protein sequences that fold into a known three-dimensional structure
US5386507A (en) * 1991-07-18 1995-01-31 Teig; Steven L. Computer graphics system for selectively modelling molecules and investigating the chemical and physical properties thereof
US5281698A (en) * 1991-07-23 1994-01-25 Cetus Oncology Corporation Preparation of an activated polymer ester for protein conjugation
ATE173763T1 (de) * 1991-08-30 1998-12-15 Hutchinson Fred Cancer Res Hybride cytokine
JP2638359B2 (ja) 1991-11-26 1997-08-06 富士通株式会社 分子動力学法の拘束条件作成装置
WO1993025687A1 (en) 1992-06-09 1993-12-23 Chiron Corporation Crystallization of m-csf
ZA933926B (en) 1992-06-17 1994-01-03 Amgen Inc Polyoxymethylene-oxyethylene copolymers in conjuction with blomolecules
US6153183A (en) 1992-11-24 2000-11-28 G. D. Searle & Company Co-administration of interleukin-3 mutant polypeptides with CSF's or cytokines for multi-lineage hematopoietic cell production
US6057133A (en) 1992-11-24 2000-05-02 G. D. Searle Multivariant human IL-3 fusion proteins and their recombinant production
US5738849A (en) 1992-11-24 1998-04-14 G. D. Searle & Co. Interleukin-3 (IL-3) variant fusion proteins, their recombinant production, and therapeutic compositions comprising them
CA2150116A1 (en) 1992-11-24 1994-06-09 S. Christopher Bauer Interleukin-3 (il-3) multiple mutation polypeptides
US5772992A (en) 1992-11-24 1998-06-30 G.D. Searle & Co. Compositions for co-administration of interleukin-3 mutants and other cytokines and hematopoietic factors
US5424963A (en) 1992-11-25 1995-06-13 Photon Research Associates, Inc. Molecular dynamics simulation method and apparatus
US5581476A (en) 1993-01-28 1996-12-03 Amgen Inc. Computer-based methods and articles of manufacture for preparing G-CSF analogs
JP2720140B2 (ja) * 1993-02-03 1998-02-25 日東化学工業株式会社 フェニル基を有する光学活性α−ヒドロキシカルボン酸の製造法
NZ281329A (en) 1994-02-23 1997-07-27 Kyowa Hakko Kogyo Kk Platelet production promoting agents comprising modified human granulocyte colony stimulating factor
US5635599A (en) 1994-04-08 1997-06-03 The United States Of America As Represented By The Department Of Health And Human Services Fusion proteins comprising circularly permuted ligands
US5576941A (en) * 1994-08-10 1996-11-19 York Technologies, Inc. Modular power supply system
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
CA2212006A1 (en) 1995-02-03 1996-08-08 G.D. Searle & Co. Novel c-mpl ligands
US6017523A (en) 1995-06-06 2000-01-25 G.D. Searle & Co. Therapeutic methods employing mutant human interleukin-3 (IL-3) polypeptides
SE9503380D0 (sv) * 1995-09-29 1995-09-29 Pharmacia Ab Protein derivatives
CA2234061A1 (en) 1995-10-05 1997-04-10 G.D. Searle & Co. Multi-functional hematopoietic receptor agonists
US6066318A (en) * 1995-10-05 2000-05-23 G.D. Searle & Co. Multi-functional hematopoietic fusion proteins between sequence rearranged C-MPL receptor agonists and other hematopoietic factors
US6100070A (en) * 1995-10-05 2000-08-08 G. D. Searle & Co. G-CSF receptor agonists
AU722759B2 (en) 1995-10-05 2000-08-10 G.D. Searle & Co. Novel C-MPL receptor agonists
NZ335382A (en) 1996-10-25 2001-03-30 Searle & Co Multi-functional chimeric hematopoietic polypeptides of IL-3, GCSF, Flt3L, EPO, stem cell factor, cmpl link with or without linker group consisting of Alanine, Glycine and/or Serine for treating autoimmune and tumour related diseases
US6660257B1 (en) 1996-10-25 2003-12-09 Pharmacia Corporation Circular permuteins of flt3 ligand
US5969105A (en) 1996-10-25 1999-10-19 Feng; Yiqing Stem cell factor receptor agonists
NZ337911A (en) 1997-04-11 2001-04-27 G flt3 ligand chimeric proteins
US6583267B2 (en) 1997-06-06 2003-06-24 Kyowa Hakko Kogyo Co., Ltd. Chemically modified polypeptides
US5985263A (en) * 1997-12-19 1999-11-16 Enzon, Inc. Substantially pure histidine-linked protein polymer conjugates
EE05214B1 (et) 1998-04-28 2009-10-15 Applied Research Systems Ars Holding N.V. Polool-IFN- β konjugaat, selle valmistamismeetod ja farmatseutiline kompositsioon
US6451986B1 (en) * 1998-06-22 2002-09-17 Immunex Corporation Site specific protein modification
EP1115854A1 (en) 1998-09-25 2001-07-18 G.D. Searle & Co. Method of producing permuteins by scanning permutagenesis
US6420339B1 (en) 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
JP2000319298A (ja) 1999-03-04 2000-11-21 Seibutsu Bunshi Kogaku Kenkyusho:Kk 蛋白質複合体の結晶、構造座標、及び構造座標の使用
KR100356140B1 (ko) 1999-07-08 2002-10-19 한미약품공업 주식회사 인간 과립구 콜로니 자극인자 변이체 및 이의 생산 방법
US6555660B2 (en) * 2000-01-10 2003-04-29 Maxygen Holdings Ltd. G-CSF conjugates
US6646110B2 (en) * 2000-01-10 2003-11-11 Maxygen Holdings Ltd. G-CSF polypeptides and conjugates
HUP0203751A3 (en) * 2000-01-10 2005-01-28 Maxygen Holdings Ltd Redwood C G-csf conjugates
US6831158B2 (en) * 2000-01-10 2004-12-14 Maxygen Holdings Ltd. G-CSF conjugates
WO2002020751A2 (en) 2000-09-07 2002-03-14 Eli Lilly And Company Hyperglycosylated polypeptides
AU2001290960B2 (en) 2000-09-08 2007-11-01 Massachusetts Institute Of Technology G-CSF analog compositions and methods
GB0022877D0 (en) 2000-09-18 2000-11-01 Isis Innovation Analogues
WO2002036626A1 (en) * 2000-11-02 2002-05-10 Maxygen Aps Single-chain multimeric polypeptides
US20020142964A1 (en) * 2000-11-02 2002-10-03 Nissen Torben Lauesgaard Single-chain polypeptides

Also Published As

Publication number Publication date
PL371781A1 (en) 2005-06-27
ATE468862T1 (de) 2010-06-15
IL159524A0 (en) 2004-06-01
AU2002325819B2 (en) 2008-06-19
US7550566B2 (en) 2009-06-23
WO2003006501A3 (en) 2004-03-25
CA2452582C (en) 2013-01-22
KR100961859B1 (ko) 2010-06-09
NZ530545A (en) 2006-10-27
WO2003006501A2 (en) 2003-01-23
US20060286069A1 (en) 2006-12-21
BR0211071A (pt) 2004-12-21
HUP0400466A2 (hu) 2005-01-28
NO20040093L (no) 2004-03-09
JP2005506317A (ja) 2005-03-03
US20110020266A1 (en) 2011-01-27
EP1425304B1 (en) 2010-05-26
CA2452582A1 (en) 2003-01-23
KR20040084884A (ko) 2004-10-06
US20070010660A1 (en) 2007-01-11
JP4444652B2 (ja) 2010-03-31
EP1425304B9 (en) 2010-09-08
US7550565B2 (en) 2009-06-23
MXPA04000231A (es) 2004-05-04
US20060286068A1 (en) 2006-12-21
EP1425304A2 (en) 2004-06-09
DE60236522D1 (de) 2010-07-08
US7696153B2 (en) 2010-04-13

Similar Documents

Publication Publication Date Title
HUP0400466A3 (en) G-csf conjugates
HUP0203751A3 (en) G-csf conjugates
AU2002351746A8 (en) Erythropoietin conjugates
GB0118651D0 (en) Flat-plate
GB0119665D0 (en) Conjugates
AU2002360430A8 (en) 14-methyl-epothilones
ZA200500199B (en) Immunogenic conjugates
HK1065063A1 (en) Oligonucleotide conjugates
HUP0201199A2 (en) Scrubbing-device
AU2002313943A8 (en) Electromobile
AU2003292197A8 (en) Lna-cpg conjugates
GB2382347B (en) Hemoglobin conjugates
AU2001100134A4 (en) Enviro-trap
ZA200204623B (en) G-CSF conjugates.
GB0111831D0 (en) Former
GB0015090D0 (en) Gene-activating conjugates
CA93075S (en) Travelbag
CA92665S (en) Bedboard
CA92978S (en) Photo-changer
AU2288P (en) Prime322 xTriticosecale
CA91502S (en) Bedboard
AU2479P (en) Crackerjack xTriticosecale
GB0127668D0 (en) Cancer
GB0115673D0 (en) Cancer
GB0123630D0 (en) cancer

Legal Events

Date Code Title Description
NF4A Restoration of patent protection
GB9A Succession in title

Owner name: MAXYGEN, INC., US

Free format text: FORMER OWNER(S): MAXYGEN HOLDINGS LTD., GB

FA9A Lapse of provisional patent protection due to relinquishment or protection considered relinquished